Author:
Laidi Charles,Prigent Amélie,Plas Alice,Leboyer Marion,Fond Guillaume,Chevreul Karine,Aouizerate B.,Andre M.,Berna F.,Capdevielle D.,Chereau-Boudet I.,Dorey J.M.,Dubertret C.,Dubreucq J.,Faget C.,Lancon C.,Leigner S.,Llorca P.M.,Mallet J.,Misdrahi D.,Rey R.,Roux P.,Schurhoff F.,Urbach M.,Vidailhet P.
Funder
FondaMental Foundation
Laboratoire d'excellence BIO-PSY
Subject
Pharmacology (medical),Biological Psychiatry,Psychiatry and Mental health,Clinical Neurology,Neurology,Pharmacology
Reference51 articles.
1. Global assessment of functioning (GAF): properties and frontier of current knowledge;Aas;Ann. Gen. Psychiatry,2010
2. Access Economics (Firm), SANE Australia, 2002. Schizophrenia: costs: an analysis of the burden of schizophrenia and related suicide in Australia / [prepared by Access Economics for SANE Australia]. SANE Australia], [South Melbourne, Vic.
3. Association, A.D., 2013. Economic Costs of Diabetes in the U.S. in 2012. Diabetes Care DC_122625. doi:10.2337/dc12-2625.
4. Assurance Maladie, 2015. Personnes prises en charge pour troubles psychotique en. Fiche pathologie. 〈https://www.ameli.fr/fileadmin/user_upload/documents/Troubles_psychotiques_2015.pdf〉.
5. Economic burden of schizophrenia in South Korea;Chang;J. Korean Med. Sci.,2008